2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Pathology, Serologic Tests, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Apoptosis, Pathogenesis, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, GVHD, Neutropenia, Infectious Diseases, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

5847 Magnetically guided ionp-engineered hucmsc exosomes alleviate acute graft-versus-host disease by restoring endothelial autophagy via the mir-143-3p/TAK1/NF-κB axis

Yifan Yao, Huafang of Wang, phD2, Li Ziying, phD3
1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Objective: Acute graft-versus-host disease (aGVHD) remains a life-threatening complication of allogeneic hematopoietic stem cell transplantation, with endothelial injury increasingly recognized as a key driver of inflammation and target-organ damage. Human umbilical cord mesenchymal stem cell-derived exosomes (hucMSC-Exos) offer a promising cell-free therapy owing to their immunomodulatory and reparative properties; however, their limited bioactivity and target-organ accumulation may compromise therapeutic efficacy. Iron oxide nanoparticle (IONP) priming combined with a static magnetic field (SMF) may enhance exosomal function and enable magnetic targeting, but its potential against aGVHD-associated endothelial injury remains unexplored. Here, we engineered IONP-hucMSC-Exos and evaluated their SMF-guided therapeutic efficacy and underlying mechanisms in aGVHD-associated endothelial injury.

Methods: IONP-hucMSC-Exos were engineered by exposing hucMSCs to PEGylated IONPs under SMF. Their therapeutic efficacy was evaluated in TNF-α-injured HUVECs and a murine model of aGVHD. Underlying mechanisms were investigated using miRNA sequencing, bioinformatics, and functional rescue assays.

Results: IONP treatment activated JNK/c-Jun pathway in hucMSCs and significantly increased the expression of the pro-reparative factors and the anti-inflammatory factors. IONP-hucMSC-Exos retained typical exosomal characteristics, exhibited magnetic responsiveness, and showed markedly enhanced uptake by HUVECs. Compared with conventional hucMSC-Exos, IONP-hucMSC-Exos more effectively promoted endothelial survival, angiogenesis, migration, and barrier repair while suppressing inflammation (IL-6 and IL-8) and enhancing autophagy (increased LC3-II/I ratio and Beclin1, decreased p62) in TNF-α-injured HUVECs. In aGVHD mouse models, SMF-directed IONP-hucMSC-Exos demonstrated targeted accumulation in affected organs, significantly improving survival rates, mitigating weight loss, and reducing clinical severity, alongside marked alleviation of histopathological damage. Additionally, combination therapy restored endothelial ultrastructural integrity in the liver and colon, accompanied by upregulated expression of the tight junction proteins ZO-1 and VE-cadherin. Moreover, this treatment was associated with enhanced endothelial autophagy, as evidenced by increased Beclin 1 expression, an elevated LC3-II/LC3-I ratio, and greater autophagosome abundance. Mechanistically, miRNA sequencing identified miR-143-3p as a key therapeutic cargo. Dual-luciferase reporter assays, qPCR, and Western blotting confirmed TAK1 as its direct target. miR-143-3p recapitulated the protective effects of IONP-hucMSC-Exos by suppressing NF-κB activation and restoring autophagy, whereas TAK1 overexpression reversed these effects. Consistently, antagomir-mediated inhibition of miR-143-3p diminished the therapeutic efficacy of IONP-hucMSC-Exos in aGVHD mice, accompanied by NF-κB reactivation and impaired autophagy in hepatic and colonic endothelial cells.

Conclusions:

Collectively, SMF-guided IONP-hucMSC-Exos enhance target-organ accumulation and alleviate aGVHD by delivering miR-143-3p to inhibit the TAK1/NF-κB axis and restore endothelial autophagy, offering a promising magnetically targeted, cell-free strategy for aGVHD.

 

Yifan Yao: No relevant conflicts of interest to declare.